Bradley G. Somer MD
Medical Oncologist; President, West Cancer Center and Research Institute; Associate Professor of Hematology/Oncology, University of Tennessee Health Science Center, Memphis, TennesseeBiographical Sketch:
Dr. Brad Somer, a medical oncologist in Memphis, Tennessee, is the President of the West Cancer Center and Research Institute, where he has practiced since 2002 after completing his fellowship training in hematology/oncology at the University of Pennsylvania Cancer Center in Philadelphia. He is one of the leaders of the most renowned multi-disciplinary comprehensive cancer center servicing the mid-south. He also serves as an assistant professor of hematology/oncology at the University of Tennessee Health Science Center.
Dr. Somer, is actively involved in clinical research in the gastrointestinal/genitourinary clinical trials program. He also serves on the NCCN panel for kidney cancer.
Dr. Somer earned his medical degree from the Albert Einstein College of Medicine in New York, with a Distinction in Research. He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While at the University of Pennsylvania, he served as assistant editor of OncoLink, a leading and award-winning cancer information website. He received his MBA at U Mass Amherst with a healthcare focus in conjunction with the American Association of Physician Leadership.
Positions:
Assistant Professor, Hematology/Oncology, University of Tennessee Health Science Center; Senior Partner, West Clinic, Memphis, Tennessee
Degrees:
MD: Albert Einstein College of Medicine, New York
Postgraduate Training:
Fellowship (hematology/oncology):University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
Clinical Interests:
Genitourinary cancer
Disclosures
Dr. Somer does not have any disclosures.Recent Contributions to PracticeUpdate:
- Cabozantinib Superior to Sunitinib as Initial Targeted Therapy in Poor- or Intermediate-Risk mRCC
- Sunitinib With Oncolytic Reovirus Ready for Clinical Testing in RCC and NSCLC
- 2016 Top Stories in RCC: Benefit of Adjuvant Therapy
- FCGR Polymorphisms Influence Response to IL-2 in mRCC
- Review of the Impact of Sunitinib in Advanced RCC
- Current Perspectives on Rx Sequencing for RCC: 3. Is There Still a Role for IL-2?
- Current Perspectives on Rx Sequencing for RCC: 2. Combination Therapy Vis-à-Vis Toxicity
- Current Perspectives on Rx Sequencing for RCC: 1. Role of mTOR Inhibitors and Cabozantinib
- ESMO 2016: Recommendations From Dr. Brad Somer
- The Obesity Paradox in RCC